Active, not recruitingPhase 2NCT06803342
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
Studying Ebola hemorrhagic fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Albert B. Sabin Vaccine Institute
- Intervention
- cAd3-Sudan Vaccine(biological)
- Enrollment
- 200 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2025 – 2027
Study locations (4)
- Synexus Clinical Research US, Inc., Phoenix, Arizona, United States
- Optimal Research; LLC, Melbourne, Florida, United States
- Synexus Clinical Research US, Inc., Chicago, Illinois, United States
- Synexus Clinical Research US, Inc., San Antonio, Texas, United States
Collaborators
Biomedical Advanced Research and Development Authority
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06803342 on ClinicalTrials.govOther trials for Ebola hemorrhagic fever
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05992480REVIVE (Response to the Ebola Virus Vaccine)Tulane University
- RECRUITINGPHASE3NCT06126822Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRCInstitute of Tropical Medicine, Belgium
- ACTIVE NOT RECRUITINGPHASE2NCT06100913Immunology of Ebola VaccineEmory University